When patients begin receiving care at St. Luke's Same Day Surgery Center in April, they'll receive medications through a computerized pharmacy system that's been in use throughout St. Luke's Regional ...
Shares of Pyxis Oncology dropped after the pharmaceutical company said data from its trials on a treatment for a form of head and neck cancer showed a high incidence of adverse effects. The stock fell ...
On Wednesday, Pyxis Oncology, Inc. (NASDAQ:PYXS) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors. Among evaluable Head and ...
Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, ...
Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...
Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors resistant to current treatments. PYXS's lead product ...
BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc., a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results